Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04)

• Status: Recruiting
• Trial end date: 2024-12-17

Summary

This study will assess safety, tolerability, and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with durvalumab in participants with advanced or metastatic non-small cell lung cancer (NSCLC).

• Phase: Phase 1

Details

• Lead Sponsor: Daiichi Sankyo, Inc.
• Collaborator: AstraZeneca
• Treatments: Carboplatin; Durvalumab